Explore. Learn. Join the conversation.

Working Group on New TB Drugs

Stop TB Partnership

22 Sep 2014

2014 WGND Annual Meeting, Barcelona, Oct. 29, 15h-19h

2014-annual-header

We invite you to join us for the Stop TB Partnership Working Group on New Drugs’ Annual Meeting 2014 at AC Hotel Barcelona Forum, Barcelona, Spain, on Wednesday, Oct. 29th from 15:00 to 19:00.

9 Sep 2014
by Working Group

Posted in Announcements, Events, TB Treatment, Uncategorized

Results of Phase III ReMoxTB Clinical Trial Published

Moxifloxacin

Results of the Phase III REMoxTB clinical trial were published in the New England Journal of Medicine on September 7th, 2014. REMox or Rapid Evaluation of Moxifloxacin in Tuberculosis (REMoxTB) was a trial designed to determine whether replacement of either ethambutol or isoniazid with moxifloxacin shortened the duration of therapy. In summary, while the regimens with moxifloxacin caused a [...]

11 Jun 2014
by Working Group

Posted in Action, Announcements, TB News, Uncategorized

Panel of TB experts releases report calling for the prioritization of tuberculosis R&D

CSIS Logo

The Center for Strategic and International Studies (CSIS) released six policy reports detailing the domestic and global health burden of tuberculosis and recommendations for the United States government to combat the disease.

Kick TB Campaign Expands to Brazil

soccerballFront-300x290

The Kick TB Campaign is a unique project that uses the World’s most popular sport to educate and engage young people in the effort to stop the spread of tuberculosis. First inaugurated in South Africa during the 2010 World Cup, Kick TB has expanded to Brazil, the host country of the 2014 World Cup.

Delamanid approved for use in the European Union

otsuka

The European Commission has approved delaminid (Deltyba) for use in patients suffering from MDR-TB.

TB Alliance launches landmark Phase 3 clinical trial aimed at shortening duration of TB treatment

TBAlliance

TB Alliance announces STAND, a Phase 3 Clinical Trial aimed at shortening the duration of treatment for drug-sensitive and MDR-TB.

27 Mar 2014
by Working Group

Posted in Announcements, TB News, TB Pediatrics, Uncategorized

TB Alliance makes series of announcements regarding new initiatives to combat childhood TB

TBAlliance

TB Alliance, an international non-profit whose mission is to develop better and more affordable drugs against tuberculosis, made three announcements on World TB Day demonstrating their commitment to combating childhood TB.

Sirturo (bedaquiline) approved for conditional use in European Union to treat MDR-TB in adults

Sirturo

The European Medicines Agency has recently approved Sirturo for conditional use in the European Union. A link to the press release is included.

26 Nov 2013

EMA Reverses Opinion on Delamanid for MDR-TB

otsuka

A European Union panel has recommended regulatory approval of a tuberculosis drug that would become only the second major new antibiotic against the deadly disease in more than 40 years.

6 Sep 2013
by Working Group

Posted in Announcements, Events

2013 WORKING GROUP ON NEW TB DRUGS ANNUAL MEETING IN PARIS, FRANCE ON OCTOBER 29TH

annual 2013

You are invited to join us for the Stop TB Partnership Working Group on New Drugs’ Annual Meeting 2013 in Paris, France on Oct. 29th. Agenda included.